Autologous SCT (ASCT) remains an effective therapy for eligible patients with myeloma

Bone Marrow Transplantation advance online publication 10 March 2008; doi: 10.1038/bmt.2008.24

Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT

S K Kumar¹, D Dingli¹, A Dispenzieri¹, M Q Lacy¹, S R Hayman¹, F K Buadi¹, S V Rajkumar¹, M R Litzow¹ and M A Gertz¹

¹Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN, USA

Correspondence: Dr SK Kumar, Department of Internal Medicine, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. E-mail: kumar.shaji@mayo.edu

Abstract

Autologous SCT (ASCT) remains an effective therapy for eligible patients with myeloma. Previous studies have suggested a lack of impact of the initial therapy on the outcome after ASCT. It is not clear if incorporation of new agents in the initial treatment regimens will have any impact on the outcome after ASCT. We studied 472 patients undergoing ASCT within 12 months of diagnosis to assess the effect of initial therapy on the outcome after ASCT. Patients received initial therapy with vincristine, adriamycin and dexamethasone (VAD), dexamethasone, thalidomide and dexamethasone or lenalidomide and dexamethasone. While patients treated with dexamethasone alone had higher disease burden at ASCT, no differences were observed in the response rates to ASCT, post transplant complications or treatment-related mortality among the groups. The median time to progression after ASCT was 27.1, 24.7, 21.1 months and did not reach the VAD, Dex, Thal–Dex and Len–Dex group, respectively, P=0.11. The median overall survival from ASCT was 62 months for VAD, 69.6 months for Dex and were not reached for Thal–Dex and Len–Dex groups, P=0.2. For patients undergoing early ASCT for myeloma, the nature of initial treatment utilized has no long-term impact on the outcome of ASCT.